Hydralazine - known culprit of drug-induced AAV How does hydral (H) AAV differ from primary (1) AAV? 💥 High dual positivity MPO/PR3 💥 DAH / pleuritis more common in H-AAV 💥 ENT, constitutional, nervous, ILD in 1-AAV 💥 More 6mo remission in H-AAV @rheumnow #ACR24 Abst 2496

In prelim analysis of this controlled clinical trial, SLE pts w/ active dse who weres given addtl NAC for 3 mos had significantly reduced dse activity. Mechanism? NAC reduces rapamycin (mTOR) activation. Common AEs: nausea, vomiting @RheumNow #ACR24 abs2677 https://t.co/E4w2Qd7RwP

• https://x.com/RHEUMarampa/status/1858907159624339570/photo/1
• https://x.com/RHEUMarampa/status/1858907159624339570/photo/1

In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA and HLA Class II #ACR24 @RheumNow ABST#2671 https://t.co/VSorAiJUIe

• https://x.com/JihaRheum/status/1858908090973786126/photo/1

SELECT-GCA suggests JAKis may be the new kid on the block Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. https://t.co/vtJzwFZMBq https://t.co/dikMRwjIZY

• SELECT-GCA suggests JAKis may be the new kid on the block | RheumNow

LEVI-04 a novel neurotropin3-i showed: -significant analgesia across all measures -improvement in functional measures and PGA for all doses in a Ph2 RCT - well tolerated Hopefully will prove to be a therapeutic option for knee #osteoarthritis in future @RheumNow #ACR24 absL15 https://t.co/kWsyyyGxyU

• https://x.com/RHEUMarampa/status/1858870754302886191/photo/1

PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE Met primary endpoint (NNT~6 for BICLA) & numerical improvements in many other endpts 1 MI & 1 death from infection over 213 pts Encouraging for sure! Second phase 3 being launched #ACR24 @RheumNow Abstr#L16 #ACRbest https://t.co/QwDMKjhFvb

• https://x.com/EBRheum/status/1858865337334211065/photo/1
• https://x.com/EBRheum/status/1858865337334211065/photo/1
• https://x.com/EBRheum/status/1858865337334211065/photo/1
• https://x.com/EBRheum/status/1858865337334211065/photo/1

#Positive #RCT of #Nipocalimab a FcRn receptor inhibitor in #Sjogrens #Disease 👏Phase 2 +RCT ESSSDAI and ESPRI both improved 🤷‍♀️what it means to lower #antibodoes #Ro #La Excited for Phase 3 results #ACRBest #ACR24 @RheumNow @ACRheum abst#2527 https://t.co/NeeYT7VR16

• https://x.com/Janetbirdope/status/1858736822970441800/photo/1
• https://x.com/Janetbirdope/status/1858736822970441800/photo/1
• https://x.com/Janetbirdope/status/1858736822970441800/photo/1

Autoantibody tests are everywhere, but how do we make sense of them? With the proper algorithms, can we go beyond interpretation to predicting autoimmunity before it develops? Check out my article: Taking the AI out of AutoImmunity https://t.co/d3ZNYWQaaQ @RheumNow #ACR24

• Taking AI Out of AutoImmunity: Predicting disease before it develops | RheumNow